CONMED Corporation (NYSE:CNMD ) Q2 2025 Earnings Conference Call July 30, 2025 4:30 PM ET Company Participants Patrick J. Beyer - President, CEO & Director Todd W.

While the top- and bottom-line numbers for Conmed (CNMD) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

CONMED Corporation (NYSE:CNMD ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Pat Beyer - Chief Executive Officer and President Todd Garner - Executive Vice Presid...

While the top- and bottom-line numbers for Conmed (CNMD) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the lat...

CNMD is poised for growth on the back of strong product offerings and recurring revenues but faces headwinds from regulatory challenges, supply-chain constraints and cybersecurity risks.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

CONMED Corporation (NYSE:CNMD ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Curt Hartman – Chairman, President and Chief Executive Officer Pat Beyer – Chief Op...

Conmed (CNMD) came out with quarterly earnings of $1.05 per share, beating the Zacks Consensus Estimate of $0.99 per share. This compares to earnings of $0.90 per share a year ago.

CNMD is poised for growth with strong product offerings and recurring revenues but faces headwinds from regulatory challenges, supply-chain constraints and cybersecurity risks.

CONMED (CNMD) beats second-quarter earnings estimates on the back of higher revenues and lower costs and expenses. However, the result reflects the continued impact of supply chain issues.

Although the revenue and EPS for Conmed (CNMD) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street...

CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.